Hsuen-Yun Hung

Title: Hsuen-Yun Hung: Innovator in Cytosolic Binding Proteins

Introduction

Hsuen-Yun Hung is a notable inventor based in East Brunswick, NJ (US). He has made significant contributions to the field of immunology through his innovative work on cytosolic binding proteins. With a total of 2 patents, his research has implications for diagnostic and therapeutic applications.

Latest Patents

Hsuen-Yun Hung's latest patents focus on the development of a new homogeneous cytosolic binding (HCB) protein. This protein exhibits a specific binding activity of about 26 µg FK-506 per mg protein and has a molecular weight of approximately 10-12 kilodaltons. It reversibly binds the immunosuppressant FK-506 but not cyclosporine A (CSA). The protein remains stable when heated at 56 degrees Celsius for 30 minutes, retaining its FK-506 binding affinity. The HCB protein is isolated from the cytosol of mammalian tissues, particularly human neoplastic T-cell lines such as Jurkat. It can be utilized in diagnostic and purification procedures involving FK-506 macrolide type immunosuppressants. Additionally, the HCB protein catalyzes the cis-trans isomerization of proline-containing peptide bonds.

Career Highlights

Hsuen-Yun Hung is currently associated with Merck & Co., Inc., where he continues to advance his research in the field of immunology. His work has garnered attention for its potential applications in medical diagnostics and therapeutics.

Collaborations

Hsuen-Yun Hung has collaborated with notable colleagues, including Richard A Mumford and John J Siekierka. Their combined expertise has contributed to the advancement of research in cytosolic binding proteins.

Conclusion

Hsuen-Yun Hung's innovative work in the development of cytosolic binding proteins highlights his significant contributions to the field of immunology. His patents reflect a commitment to advancing medical science and improving therapeutic options.